Brenner W, Bohuslavizki K H, Wolf H, Sippel C, Clausen M, Henze E
Clinic of Nuclear Medicine, Christian-Albrechts-University of Kiel, Arnold-Heller-Strasse 9, D-24105 Kiel, Germany.
Eur J Nucl Med. 1996 Jan;23(1):91-4. doi: 10.1007/BF01736995.
Malignant struma ovarii is a very rare disease and, therefore, there is neither common agreement on treatment regimens nor sufficient follow-up experience. We present a case of a 49-year-old woman with malignant struma ovarii of the follicular type, who received ablative radioiodine treatment after thyroidectomy and surgical removal of the primary tumour. During follow-up examinations an increasing thyroglobulin level was found, caused by a tumour relapse with suspected urinary bladder infiltration on CT and proven uptake of radioiodine on whole-body scanning with iodine-131. After administration of 6GBq 131I, complete tumour regression was achieved with no evidence of a new relapse during a 30-month follow-up period. Correspondingly, repeated thyroglobulin measurements were all negative. This case demonstrates the benefit of combined surgical and radioiodine treatment of malignant struma ovarii for both monitoring and therapy of relapse or metastases; thus, the same therapeutic regimen as is employed in primary differentiated thyroid carcinoma may be recommended.
恶性卵巢甲状腺肿是一种非常罕见的疾病，因此，对于治疗方案既没有达成共识，也没有足够的随访经验。我们报告一例49岁的滤泡型恶性卵巢甲状腺肿女性患者，该患者在甲状腺切除及原发肿瘤手术切除后接受了放射性碘消融治疗。在随访检查中，发现甲状腺球蛋白水平升高，CT检查怀疑肿瘤复发并浸润膀胱，131碘全身扫描证实有放射性碘摄取。给予6GBq 131I后，肿瘤完全消退，在30个月的随访期内没有新的复发迹象。相应地，重复检测甲状腺球蛋白均为阴性。该病例表明，手术和放射性碘联合治疗恶性卵巢甲状腺肿对复发或转移的监测和治疗均有益处；因此，可推荐采用与原发性分化型甲状腺癌相同的治疗方案。
